Roche Holding AG
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after Roche presented po...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United ...
Latest News
3 days ago · prnewswire.com
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needsThe new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to inform timely patient management. Laboratories can optimize resources with up to five flexible panel configurations tailored to local disease prevalence and patient needs, enabled by cobas® eplex system software version 3.0 or higher.
8 days ago · seekingalpha.com
Roche: Valuation Leaves Limited UpsideRoche delivered 7% Q3 sales growth at constant currency, although approximately CHF 180 million was attributable to shipments that had been brought forward in Japan. Pharmaceuticals performed well, but Chinese pricing reforms continue to weigh on Diagnostics, while FX remains a headwind to reported earnings. Giredestrant and fenebrutinib offer future growth opportunities, although regulatory approvals and commercial performance remain important uncertainties.
9 days ago · seekingalpha.com
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And DetractorsMicrosoft Corporation was the portfolio's top contributor during the quarter. Suncor Energy outperformed the Index during the quarter. KLA Corporation traded lower during the quarter.
11 days ago · wsj.com
Roche Targets Emerging Oncology Market With New Lung-Cancer DrugThe Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology market.
11 days ago · reuters.com
Roche says divarasib cut risk of death 44% in lung cancer trialRoche says divarasib cut risk of death 44% in lung cancer trial
11 days ago · globenewswire.com
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerBasel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
11 days ago · businesswire.com
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung CancerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.
13 days ago · businesswire.com
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today late-breaking oral presentation data from the ongoing Phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
13 days ago · globenewswire.com
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P
14 days ago · seekingalpha.com
Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call TranscriptRoche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
Add to Watchlist
Select watchlists to add or remove RHHVF